Patents by Inventor Gregg Stetsko
Gregg Stetsko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160120950Abstract: The present disclosure is directed to stable pharmaceutical formulations and uses thereof.Type: ApplicationFiled: October 30, 2015Publication date: May 5, 2016Applicants: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Robert N. Jennings, John T.H. Ong, Christopher A. Rhodes, Gregg Stetsko, Steven J. Prestrelski
-
Publication number: 20150157725Abstract: Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing mixture of a cationic polyamino acid, at least one additional absorption enhancing agent, and a buffer that is compatible with the polyamino acid. Also provided are methods for enhancing the transmucosal absorption and bioavailability of bioactive peptides and proteins using such compositions.Type: ApplicationFiled: December 15, 2014Publication date: June 11, 2015Inventors: John ONG, Robert JENNINGS, Christopher RHODES, Gregg STETSKO
-
Publication number: 20150111824Abstract: The present disclosure is directed to stable pharmaceutical formulations and uses thereof.Type: ApplicationFiled: October 28, 2014Publication date: April 23, 2015Inventors: Robert N. JENNINGS, John T.H. ONG, Christopher A. RHODES, Gregg STETSKO, Steven J. PRESTRELSKI
-
Patent number: 8008255Abstract: Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing mixture of a cationic polyamino acid and a buffer that is compatible with the polyamino acid. Also provided are methods for enhancing the transmucosal absorption and bioavailability of bioactive peptides and proteins using such compositions.Type: GrantFiled: May 28, 2004Date of Patent: August 30, 2011Assignee: Amylin Pharmaceuticals, Inc.Inventors: John Ong, Robert Jennings, Gregg Stetsko
-
Publication number: 20090291886Abstract: Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing mixture of a cationic polyamino acid and a buffer that is compatible with the polyamino acid. Also provided are methods for enhancing the transmucosal absorption and bioavailability of bioactive peptides and proteins using such compositions.Type: ApplicationFiled: May 5, 2008Publication date: November 26, 2009Applicant: Amylin Pharmaceuticals, Inc.Inventors: John Ong, Robert Jennings, Christopher Rhodes, Gregg Stetsko
-
Publication number: 20090069226Abstract: Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing mixture of a cationic polyamino acid, at least one additional absorption enhancing agent, and a buffer that is compatible with the polyamino acid. Also provided are methods for enhancing the transmucosal absorption and bioavailability of bioactive peptides and proteins using such compositions.Type: ApplicationFiled: January 12, 2005Publication date: March 12, 2009Applicant: Amylin Pharmaceuticals, Inc.Inventors: John Ong, Robert Jennings, Christopher Rhodes, Gregg Stetsko
-
Publication number: 20090018053Abstract: The present invention is concerned with a pharmaceutical formulation comprising an amylin agonist and optionally a buffer, a tonicifier or stabilizer, and a preservative in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen. This formulation may be in liquid, gel, solid or powdered form for delivery, for example, via nasal, pulmonary, oral, sublingual, buccal, transdermal, or parenteral routes. Formulation with biocompatible polymers and release modifiers, such as sugars, can facilitate controlled release after injection, minimizing the number of administrations to a patient. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin for administration to a patient.Type: ApplicationFiled: December 20, 2007Publication date: January 15, 2009Applicant: Amylin Pharmaceuticals, Inc.Inventors: James L. L'ITALIEN, Gregg STETSKO
-
Publication number: 20080200383Abstract: The present disclosure is directed to stable pharmaceutical formulations and uses thereof.Type: ApplicationFiled: April 6, 2006Publication date: August 21, 2008Applicant: Amylin Pharmaceuticals, Inc.Inventors: Robert N. Jennings, John T.H. Ong, Christopher A. Rhodes, Gregg Stetsko, Steven J. Prestrelski
-
Patent number: 7312196Abstract: The present invention is concerned with a pharmaceutical formulation comprising an amylin agonist and optionally a buffer, a tonicifier or stabilizer, and a preservative in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen. This formulation may be in liquid, gel, solid or powdered form for delivery, for example, via nasal, pulmonary, oral, sublingual, buccal, transdermal, or parenteral routes. Formulation with biocompatible polymers and release modifiers, such as sugars, can facilitate controlled release after injection, minimizing the number of administrations to a patient. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin for administration to a patient.Type: GrantFiled: May 31, 2002Date of Patent: December 25, 2007Assignee: Amylin Pharmaceuticals, Inc.Inventors: James L'Italien, Gregg Stetsko
-
Publication number: 20060172001Abstract: Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing mixture of a cationic polyamino acid and a buffer that is compatible with the polyamino acid. Also provided are methods for enhancing the transmucosal absorption and bioavailability of bioactive peptides and proteins using such compositions.Type: ApplicationFiled: May 28, 2004Publication date: August 3, 2006Applicant: Amylin Pharmaceuticals, Inc.Inventors: John Ong, Robert Jennings, Gregg Stetsko
-
Publication number: 20050215475Abstract: Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing mixture of a cationic polyamino acid, at least one additional absorption enhancing agent, and a buffer that is compatible with the polyamino acid. Also provided are methods for enhancing the transmucosal absorption and bioavailability of bioactive peptides and proteins using such compositions.Type: ApplicationFiled: January 12, 2005Publication date: September 29, 2005Inventors: John Ong, Robert Jennings, Christopher Rhodes, Gregg Stetsko
-
Publication number: 20030092606Abstract: The present invention is concerned with a pharmaceutical formulation comprising an amylin agonist and optionally a buffer, a tonicifier or stabilizer, and a preservative in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen. This formulation may be in liquid, gel, solid or powdered form for delivery, for example, via nasal, pulmonary, oral, sublingual, buccal, transdermal, or parenteral routes. Formulation with biocompatible polymers and release modifiers, such as sugars, can facilitate controlled release after injection, minimizing the number of administrations to a patient. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin for administration to a patient.Type: ApplicationFiled: May 31, 2002Publication date: May 15, 2003Inventors: James L'Italien, Gregg Stetsko
-
Patent number: 5573783Abstract: A pharmaceutical film matrix comprising nanoparticles of a low solubility drug associated with a steric stabilizer and a film dispersing agent is coated on the surface of carrier particles and overcoated with a protective layer. Pharmaceutical compositions comprising the film matrix-coated carrier exhibit excellent bioavailability, are useful in methods of treating mammals and are extremely stable in that they are capable of being redispersed without extensive agglomeration into larger particles after being stored.Type: GrantFiled: February 13, 1995Date of Patent: November 12, 1996Assignee: Nano Systems L.L.C.Inventors: Mark A. Desieno, Gregg Stetsko
-
Patent number: 5340589Abstract: Low solubility drug coated bead compositions, capsules filled therewith and method of preparation thereof, especially wherein the low solubility drug is an antiandrogenic steroid and most especially wherein the antiandrogenic steroid is (5.alpha.,17.alpha.)-1'-(methylsulfonyl)- 1'-H-pregn-20-yno[3,2-c]pyrazol-17-ol, are disclosed.Type: GrantFiled: May 12, 1993Date of Patent: August 23, 1994Assignee: Sterling Winthrop Inc.Inventors: Gregg Stetsko, Kuei-Tu Chang
-
Patent number: 5330759Abstract: Soft capsules coated with an enteric coating comprising a 1:1 copolymer of methacrylic acid and methyl or ethyl acrylate or methyl or ethyl methacrylate and a plasticizer without need for a subcoating and optionally additionally coated with a protective coating comprising hydroxypropyl methylcellulose or hydroxypropyl cellulose or a mixture thereof and a plasticizer and method of preparation thereof are disclosed.Type: GrantFiled: August 26, 1992Date of Patent: July 19, 1994Assignee: Sterling Winthrop Inc.Inventors: Shrikant N. Pagay, Gregg Stetsko
-
Patent number: 5223268Abstract: Low solubility drug coated bead compositions, capsules filled therewith and method of preparation thereof, especially wherein the low solubility drug is an antiandrogenic steroid and most especially wherein the antiandrogenic steroid is (5.alpha.,17.alpha.)1'-(methylsulfonyl)-1'H-pregn-20-yno[3,2-c]pyrazol-17- ol, are disclosed.Type: GrantFiled: May 16, 1991Date of Patent: June 29, 1993Assignee: Sterling Drug, Inc.Inventors: Gregg Stetsko, Kuei-Tu Chang
-
Patent number: 5213811Abstract: Sugar or sugar/starch beads coated with a first coating of a drug, for example 1,2-dihydro-6-(lower alkyl)-2-oxo-5-(4-pyridinyl)-nicotinonitrile (milrinone), hydroxypropyl methylcellulose or hydroxypropyl cellulose and a plasticizer selected from triacetin, diacetylated monoglycerides, glycerin, propylene glycol, polyethylene glycol, diethyl phthalate and triethyl citrate or a mixture of two or more thereof and a second coating of high-viscosity ethylcellulose, low-viscosity ethylcellulose, hydroxypropyl cellulose, polyvinyl acetate phthalate and a plasticizer selected from diacetylated monoglycerides and triacetin or a mixture thereof and optionally coated with additional first coating and capsules filled therewith and method of preparation thereof are disclosed.Type: GrantFiled: September 13, 1991Date of Patent: May 25, 1993Assignee: Sterling Drug Inc.Inventors: Steven E. Frisbee, Gregg Stetsko, Margaret A. Lawton
-
Patent number: 5047258Abstract: A process for spray-coating tablets and the like utilizing only an acrylate enteric polymer and plasticizer in water is disclosed. The process can be practiced on a commercial scale and requires no antiadherent in the coating formulation. The process comprises providing inlet air having a dew point below about 10.degree. C. and a temperature between 35.degree. and 60.degree. C.Type: GrantFiled: December 4, 1990Date of Patent: September 10, 1991Assignee: Sterling Drug Inc.Inventors: Raymond J. Belanger, Gregg Stetsko, Shrikant N. Pagay